Omeros drug fails a PhIII kidney trial, stock nearly halved
Omeros said Monday that its treatment candidate for a certain kidney disease failed a Phase III study, and investors shaved nearly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
